Novel Muscle Therapeutics Through Selective Beta-Adrenoceptor Signalling

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1026231

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Muscle wasting is an urgent and unmet health risk commonly associated with ageing; cancer, muscle diseases, and conditions including cardiovascular and metabolic disorders. Manipulating beta-adrenergic signalling is a therapeutic target for muscle wasting but treatments have so far been limited due to cardiaovascular side effects. Using cutting edge technologies, we will identify treatments that effectively separate beneficial effects on skeletal muscles from unwanted effects on the heart.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $603,608.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Gene and Molecular Therapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

beta-adrenoceptor subtypes | muscle growth factors | signalling pathways | skeletal muscle hypertrophy | skeletal muscle wasting

Related Links